These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 19507458

  • 1. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.
    Swenson KK, Nissen MJ, Anderson E, Shapiro A, Schousboe J, Leach J.
    J Support Oncol; 2009; 7(3):101-7. PubMed ID: 19507458
    [Abstract] [Full Text] [Related]

  • 2. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [Abstract] [Full Text] [Related]

  • 3. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, Austrian Breast and Colorectal Cancer Study Group.
    J Clin Oncol; 2007 Mar 01; 25(7):820-8. PubMed ID: 17159195
    [Abstract] [Full Text] [Related]

  • 4. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
    Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE.
    Cancer; 2008 Mar 01; 112(5):1001-10. PubMed ID: 18205185
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
    Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA.
    J Clin Oncol; 2007 Mar 01; 25(7):829-36. PubMed ID: 17159193
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
    Lancet Oncol; 2008 Sep 01; 9(9):840-9. PubMed ID: 18718815
    [Abstract] [Full Text] [Related]

  • 10. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
    Lee SA, Hwang SH, Ahn SG, Lee HM, Jeong J, Lee HD.
    Breast Cancer Res Treat; 2011 Dec 01; 130(3):863-70. PubMed ID: 21861101
    [Abstract] [Full Text] [Related]

  • 11. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.
    Urology; 2007 Jul 01; 70(1):122-6. PubMed ID: 17656221
    [Abstract] [Full Text] [Related]

  • 12. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
    Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA.
    Cancer; 2012 Mar 01; 118(5):1192-201. PubMed ID: 21987386
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE.
    Cancer Treat Rev; 2008 Mar 01; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [Abstract] [Full Text] [Related]

  • 18. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S.
    Cancer; 2009 Aug 01; 115(15):3468-74. PubMed ID: 19484786
    [Abstract] [Full Text] [Related]

  • 19. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DN, Warsi GM, Lacerna LV.
    Clin Genitourin Cancer; 2007 Mar 01; 5(4):271-7. PubMed ID: 17553207
    [Abstract] [Full Text] [Related]

  • 20. Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer.
    Swenson KK, Henly SJ, Shapiro AC, Schroeder LM.
    Clin J Oncol Nurs; 2005 Apr 01; 9(2):177-84. PubMed ID: 15853161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.